Stay updated on Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial
Sign up to get notified when there's something new on the Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial page.

Latest updates to the Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe study record page now shows a 403 Forbidden message with a minimal header and a Home link, indicating restricted access rather than changes to the study details.SummaryDifference16%

- Check18 days agoChange DetectedThe page now displays Revision: v3.7.0, replacing the previous v3.6.6. This indicates a site-wide update rather than a modification to the study content.SummaryDifference0.0%

- Check32 days agoChange DetectedRevision: v3.6.6 appears, replacing v3.6.5; this denotes a page version update rather than substantive content changes to the study details.SummaryDifference0.0%

- Check53 days agoChange DetectedThe study details page updated to revision v3.6.5. Sponsor attribution and some helper-link sections were removed, changing how the sponsor information and navigation are presented.SummaryDifference0.1%

- Check74 days agoChange DetectedNew sections More Information and Helpful Links Provided by Naurex, Inc, an affiliate of Allergan plc have been added, and the revision notice was updated from v3.6.3 to v3.6.4.SummaryDifference0.1%

- Check81 days agoChange DetectedRemoved sponsor attribution and footer help sections from the study page. This includes the Naurex, Inc, an affiliate of Allergan plc sponsor line and the 'More Information' and 'Helpful Links Provided by' areas.SummaryDifference0.1%

Stay in the know with updates to Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial page.